{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:09:31Z","timestamp":1787069371182,"version":"build-2736575974"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding characteristics and reasons associated with using calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) for migraine prevention may help clinicians individualize treatment plans and achieve better patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 2019\u20132020 cohort data of OVERCOME (US), a population-based survey among adults with migraine. Eligible participants were categorized based on current CGRP mAb usage (\u201cNEVER\u201d and \u201cEVER\u201d users [\u201cContinued\u201d, \u201cSwitched\u201d and \u201cDiscontinued\u201d]). Machine learning techniques followed by logistic regression were used to examine, among 60 sociodemographic, clinical, migraine-related- and migraine treatment utilization characteristics, those associated with CGRP mAb use status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 39,113 participants, 25.6% had ever used migraine preventive medication(s) and 5.0% used CGRP mAbs (of which 46.1% Continued, 14.7% Switched and 39.3% Discontinued). Top factors associated with higher odds of CGRP mAb EVER vs. NEVER use were currently using recommended acute medication (odds ratio (OR)\u2005=\u20052.43; 95% confidence interval (CI)\u2005=\u20052.09\u20132.82) and contraindications for triptan use (OR\u2005=\u20052.32; 95% CI\u2005=\u20052.06\u20132.60). Continuing use vs. switching or discontinuing was most associated with current use of botulinum toxin for migraine (OR\u2005=\u20052.21; 95% CI\u2005=\u20051.42\u20133.44 and OR\u2005=\u20054.53; 95% CI\u2005=\u20053.14\u20136.55, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At the time of survey, CGRP-targeted mAbs remain underutilized for migraine and multiple characteristics are associated with CGRP mAb use patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251341243","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:07:56Z","timestamp":1749697676000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-6640","authenticated-orcid":false,"given":"Sait","family":"Ashina","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center"},{"name":"Harvard Medical School"},{"name":"Beth Israel Deaconess Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-6644","authenticated-orcid":false,"given":"Gilwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jolanda","family":"Muenzel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Zagar","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Zakharyan","sequence":"additional","affiliation":[{"name":"Statistics, TechData Service Company, LLC, King of Prussia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"University of Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2725-9739","authenticated-orcid":false,"given":"Robert A.","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Pearlman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32160-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000654"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00530-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0250-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01476-y"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14259"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14729"},{"key":"e_1_3_3_18_2","unstructured":"US Food and Drug Administration. AIMOVIG\u2122 (erenumab) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf (accessed 25 July 2024)."},{"key":"e_1_3_3_19_2","unstructured":"US Food and Drug Administration. AJOVY\u2122 (fremanezumab) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761089s000lbl.pdf (accessed 25 July 2024)."},{"key":"e_1_3_3_20_2","unstructured":"US Food and Drug Administration. EMGALITY (galcanezumab) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761063s000lbl.pdf (accessed 25 July 2024)."},{"key":"e_1_3_3_21_2","unstructured":"US Food and Drug Administration. VYEPTI\u2122 (eptinezumab) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf (accessed 25 July 2024)."},{"key":"e_1_3_3_22_2","unstructured":"US Food and Drug Administration. NURTEC (rimegepant) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212728s006lbl.pdf (accessed 31 October 2024)."},{"key":"e_1_3_3_23_2","unstructured":"US Food and Drug Administration. QULIPTA (atogepant) Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf (accessed 31 October 2024)."},{"key":"e_1_3_3_24_2","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen J","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.","edition":"2"},{"key":"e_1_3_3_25_2","first-page":"5","volume-title":"Random forests. Machine learning","author":"Breiman L.","year":"2001","unstructured":"Breiman L. Random forests. Machine learning. Springer, 2001, 45, pp.5\u201332. https:\/\/doi.org\/10.1023\/A:1010933404324"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x"},{"key":"e_1_3_3_27_2","unstructured":"Breiman L Cutler A. Manual-setting up using and understanding random forests https:\/\/www.stat.berkeley.edu\/\u223cbreiman\/Using_random_forests_V3.1.pdf (2003 accessed 31 October 2024)."},{"key":"e_1_3_3_28_2","unstructured":"The HPFOREST Procedure: Loss Reduction. SAS Institute Inc. SAS\u00ae Enterprise Miner\u2122 14.2: High-Performance Procedures. Cary NC: SAS Institute Inc https:\/\/documentation.sas.com\/doc\/en\/emhpprcref\/14.2\/emhpprcref_hpforest_details29.htm (2016 Accessed 31 October 2024."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00264-x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab093"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01103-8"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0615-6"},{"key":"e_1_3_3_34_2","first-page":"421","article-title":"Patterns of use of monoclonal antibodies for the preventive treatment of migraine: results from the OVERCOME (EU) study","volume":"29","author":"Pascual J","year":"2022","unstructured":"Pascual J, Novick D, Panni T, et al. Patterns of use of monoclonal antibodies for the preventive treatment of migraine: results from the OVERCOME (EU) study. EPO-078. Eur J Neurol 2022; 29: 421\u2013421.","journal-title":"EPO-078. Eur J Neurol"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251341243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251341243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251341243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:55Z","timestamp":1777387615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251341243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/03331024251341243"],"URL":"https:\/\/doi.org\/10.1177\/03331024251341243","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"03331024251341243"}}